








































































- R-B27	as	described	above	 is	stable	 for	approximately	2	weeks	at	4°C.	Using	media	beyond	2	weeks	
may	adversely	affect	T	cell	differentiation.			















1. Make	 single	 cell	 suspensions	 from	CB,	 BM,	MPB,	 or	 PB	 by	 diluting	 samples	 4X	with	 sterile	 PBS.	 Isolate	
mononuclear	cells	(MNCs)	by	Ficoll-Paque	gradient	centrifugation	as	per	manufacturer	instructions.	(This	
step	is	not	required	for	thymic	samples).		
2. Proceed	 to	CD34+	enrichment	of	MNCs	using	 the	CD34	MicroBead	UltraPure	 kit	 and	magnetic-assisted	
cell	sorting	(MACS)	(Miltenyi)	following	the	manufacturer’s	instructions.	






- FACS	 purification	 using	 anti-CD34	 and	 anti-CD3	 antibodies	 is	 highly	 recommended	 to	 remove	
contaminating	mature	T	cells,	which	will	proliferate	in	ATOs	and	may	lead	to	misinterpretation	of	 in	
vitro	T	cell	differentiation	data.		
- MACS-enriched	 CD34+	 cells	 from	 the	 different	 sources	 can	 be	 cryopreserved	 after	 magnetic	
separation	 in	 FBS/10%	 DMSA	 and	 stored	 in	 liquid	 nitrogen.	 When	 cells	 are	 needed,	 they	 can	 be	
thawed	 and	 resuspended	 in	 MACS	 buffer	 (PBS/0.5%	 BSA/2	 mM	 EDTA)	 before	 proceeding	 to	
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CD34+CD3-	 purification	 by	 FACS	 as	 above.	 We	 do	 not	 recommend	 cryopreserving	 whole	 MNC	
fractions	prior	to	CD34	enrichment	by	MACS.			
- If	 lentivirus-transduced	CD34+	cells	are	 required	 for	use	 in	ATOs,	proceed	 to	 lentiviral	 transduction	
immediately	 after	 FACS	 purification	 step.	 We	 typically	 activate	 HSPCs	 for	 12-18h,	 followed	 by	

















































- Because	 of	 the	 thickness	 of	 the	 cell	 slurry,	 the	 step	 of	 adjusting	 the	 volume	 can	 be	 challenging.	 If	

























Supp.	 Protocol	 Fig.	 1:	 	 a)	
Schematic	 of	 the	 ATO	
system.	 b)	 Generation	 of	
ATOs.	 Top	 row:	 deploying	









- ATO	 complete	medium	 (R-B27	 complete	medium	 +	 cytokines	 )	 is	 changed	 every	 3-4	 days.	 During	 this	
process,	the	ATO	should	never	be	disrupted.		
	










- Cells	can	be	harvested	at	any	time	point	 from	ATOs.	 If	 large	numbers	of	T	cells	are	required,	cells	 from	
multiple	ATOs	can	be	harvested	and	pooled.			
	
1. Using	a	P-1000,	add	1	mL	of	cold	MACS	buffer	 (PBS/0.5%	BSA/2mM	EDTA)	on	to	the	surface	of	 the	cell	
culture	insert,	immersing	the	ATO	
2. Pipette	up	and	down	several	times	to	detach	the	ATO	from	the	insert	membrane	and	mechanically	disrupt	




4. Wash	 the	 cell	 insert	 and	well	 3-4	 times	with	 cold	MACS	 buffer	 and	 transfer	 all	 washes	 to	 the	 original	
collection	tube.	








- If	 cell	 analysis	 at	 multiple	 time	 points	 is	 needed,	 individual	 ATOs	 should	 be	 generated	 for	 each	
































- Variable	depending	on	 the	 type	and	number	of	 samples	but	 is	usually	 about	2	hours	 for	 the	 combined	
Ficoll	and	MACS	steps.	
- FACS	purification	of	CD34+	cells	usually	takes	2	hours	(including	antibody	staining	and	cell	sorting).	Thus,	
the	 preparation	 of	 HSPCs	 can	 be	 accomplished	 in	 4	 hours	 (or	 only	 2	 hours	 if	 the	 CD34+	 cells	 were	
previously	enriched	by	MACS	and	frozen).		
MS5-hDLL1	preparation:	
- Harvesting	 MS5-hDLL1	 cells	 for	 ATOs	 usually	 takes	 between	 30	 minutes	 to	 1	 hour,	 depending	 of	 the	
number	of	flasks	used,	and	can	be	done	while	the	HSPCs	are	being	isolated.		
ATO	generation:	


















- ATO	 cell	 phenotypes,	 differentiation	 kinetics,	 and	 cell	 yields	 are	 extensively	 characterized	 in	 the	
accompanying	article.	A	 list	of	monoclonal	antibodies	used	 for	standard	 flow	cytometric	analysis	of	
ATOs	is	listed	in	the	Online	Methods	section	of	the	accompanying	article.	
	
- Flow	cytometric	 analysis	 of	ATO	 cells	 should	 include	at	minimum	a	 viability	dye	 (e.g.	DAPI)	 for	 the	
exclusion	 of	 dead	 cells,	 and	 staining	 for	 either	 human	 CD45	 or	 mouse	 CD29	 to	 gate	 on	 human	
hematopoietic	cells	or	gate	out	MS5-hDLL1	cells,	respectively.	This	is	particularly	important	if	FITC	or	
eGFP	are	used	 in	 the	 study,	 as	MS5-hDLL1	 cells	express	eGFP	and	may	confound	analysis.	We	also	
highly	 recommend	 that	 labeling	 for	 human	 CD14	 be	 included	 in	 any	 analysis	 panel	 to	 gate	 out	



















- Within	 the	 CD3+TCRαβ+CD8SP	 and	 CD4SP	 populations,	 immature	 naïve	 T	 cells	 with	 a	 DP-like	
phenotype	 (CD45RA-CD45RO+CD1ahigh)	 can	 be	 further	 differentiated	 from	 mature	 naïve	 T	 cells	
(CD45RA+CD45RO-CD1alo).	The	frequency	of	cells	with	the	mature	naïve	phenotype	increases	in	ATOs	
between	weeks	6-12.		
	
- Care	must	be	taken	when	analyzing	CD8+	and	CD4+	T	cells	in	ATOs,	as	it	is	insufficient	to	define	these	
populations	based	on	single	markers,	as	both	CD4ISP	and	CD8aa+	innate	lymphoid	cells	are	present	in	
ATOs	and	confound	this	analysis.	Rather,	gating	on	CD3+,	TCRαβ+,	or	both	markers	 first	will	assure	
gating	on	true	mature	T	cells.		
	
- Examination	of	total	T-lineage	cells	(CD7+CD5+)	provides	a	simple	read	out	of	T	cell	differentiation	in	
ATOs	at	any	time	point,	however	does	not	give	an	indication	as	to	T	cell	developmental	stage.	
	
- An	ATO	made	from	7500	cord	blood	HSPCs	should	give	rise	to	an	average	of	1.5	to	2x106	total	cells	at	
week	6.	Higher	cell	numbers	are	seen	with	TCR-transduced	CB	HSPCs.	The	fraction	of	total	cells	that	
are	mature	CD3+TCRαβ+CD8SP	or	CD4SP	T	cells	depends	on	the	timepoint	of	harvesting,	with	percent	
mature	cells	increasing	progressively	between	weeks	6-12.	
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